CompletedHealthcare23 October 2026

Bolt Biotherapeutics, Inc. to acquire Prana Therapies, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Bolt Biotherapeutics, Inc.
Target
Prana Therapies, Inc.
Deal value
Not disclosed
Announced
23 October 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
shares
What we know

Bolt Biotherapeutics, Inc. completed its acquisition of Prana Therapies, Inc. on October 23, 2026, under an Agreement and Plan of Merger dated the same day. The deal was structured in two steps. Prince Merger Sub I, Inc. merged into Prana, which survived as a wholly owned Bolt subsidiary. Prana then merged into Prince Merger Sub II, LLC, which survived. Bolt describes the merger as intended to qualify as a tax-free reorganization for U.S. federal income tax purposes, and each Prana stock option was assumed by Bolt and converted into an option to purchase Bolt common stock.

Bolt issued Prana stockholders 430,746 shares of common stock and 16,360.929 shares of Series D Non-Voting Convertible Preferred Stock. Each preferred share converts into 1,000 common shares, but only after Bolt stockholders approve the required matters and subject to beneficial ownership limits that each holder sets between 4.99% and 19.99%. Immediately after closing and before the financing, assuming the preferred converts, Bolt reports that its pre-transaction equityholders hold about 11.8% of its common stock and former Prana equityholders about 88.2%, calculated on a fully diluted basis using the treasury stock method.

The merger did not need Bolt stockholder approval. Bolt has agreed to hold stockholder meetings on the conversion of the Series D Preferred Stock and on Nasdaq-related proposals, among other matters. Certain officers, directors and stockholders of Prana, and certain directors and officers of Bolt, signed 180-day lock-up agreements covering common and preferred shares they held at closing.

Separately, on October 23, 2026, Bolt signed a Securities Purchase Agreement to sell 13,995.311 shares of Series D Preferred Stock with warrants for aggregate upfront gross proceeds of $120 million. That financing was expected to close on October 26, 2026, subject to closing conditions, and is distinct from the merger consideration. If the warrants were exercised in full for cash, Bolt would receive about $60 million more, though the filing states there is no assurance any will be exercised. Under the Merger Agreement, Bolt must file a resale registration statement for the merger shares and the shares underlying the preferred within 75 days following the closing date.

Deal timeline

1 update
  1. CompletedClosed

    Bolt Biotherapeutics, Inc. completes acquisition of Prana Therapies, Inc.

    Item 1.01 - Entry into a Material Definitive Agreement. Agreement and Plan of Merger On October 23, 2026, Bolt Biotherapeutics, Inc., a Delaware corporation (the “ Company ” or “ Bolt ”), acquired Prana Therapies, Inc., a Delaware corporation (“ Prana ”), in accordance with the terms of the Agreement and Plan of Merger, dated October 23, 2026 (the “ Merger Agreement ”), by and among the Company, P

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Bolt Biotherapeutics, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive